Match!

Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases

Published on 2019in Langenbeck's Archives of Surgery2.09
· DOI :10.1007/s00423-019-01805-x
Vignesh Narasimhan2
Estimated H-index: 2
(Peter MacCallum Cancer Centre),
Atandrila Das (Peter MacCallum Cancer Centre)+ 6 AuthorsAlexander G. Heriot39
Estimated H-index: 39
(Peter MacCallum Cancer Centre)
Cite
Abstract
Background Peritoneal surface malignancy (PSM) was historically associated with a poor survival. The adoption of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) can now offer patients with PSM a favourable overall survival. Here, we report our single-institute outcomes following CRS and HIPEC for PSM and evaluate changes in our practice over time.
  • References (40)
  • Citations (0)
Cite
References40
Newest
Published on Apr 25, 2019in BMC Cancer2.93
Koen P. Rovers , Koen P. Rovers + 56 AuthorsE. Madsen1
Estimated H-index: 1
(EUR: Erasmus University Rotterdam)
Background Upfront cytoreductive surgery with HIPEC (CRS-HIPEC) is the standard treatment for isolated resectable colorectal peritoneal metastases (PM) in the Netherlands. This study investigates whether addition of perioperative systemic therapy to CRS-HIPEC improves oncological outcomes.
Published on May 1, 2019in The Lancet59.10
Tony Mok71
Estimated H-index: 71
(CUHK: The Chinese University of Hong Kong),
Yi-Long Wu58
Estimated H-index: 58
(Academy of Medical Sciences, United Kingdom)
+ 246 AuthorsKonstantin K Laktionov1
Estimated H-index: 1
Summary Background First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater. We investigated overall survival after treatment with pembrolizumab monotherapy in patients with a PD-L1 TPS of 1% or greater. Methods This randomised, open-label, phase 3 study was done in 213 medical centres in 32 countries. Eligible patien...
Published on Apr 8, 2019in Annals of Surgical Oncology3.68
Zachary E. Stiles3
Estimated H-index: 3
(UTHSC: University of Tennessee Health Science Center),
Andrew J. Murphy2
Estimated H-index: 2
(UTHSC: University of Tennessee Health Science Center)
+ 9 AuthorsWayne L. Furman41
Estimated H-index: 41
(St. Jude Children's Research Hospital)
Background Desmoplastic small round cell tumor (DSRCT) is a rare intra-abdominal soft tissue sarcoma affecting adolescents and young adults. Cytoreduction, hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), and adjuvant radiotherapy may improve local control. We review our experience with patients who undergo CRS/HIPEC and adjuvant radiotherapy for DSRCT.
Published on Dec 16, 2018in Journal of Surgical Oncology3.11
Nayef A. Alzahrani9
Estimated H-index: 9
(UNSW: University of New South Wales),
Sarah J. Valle5
Estimated H-index: 5
(UNSW: University of New South Wales)
+ 24 AuthorsI. H. J. T. de Hingh36
Estimated H-index: 36
Published on Jun 20, 2018in Journal of Clinical Oncology28.25
F. Quenet23
Estimated H-index: 23
,
D. Elias80
Estimated H-index: 80
+ 14 AuthorsG. Lorimier18
Estimated H-index: 18
LBA3503Background: Promising results have been obtained during the last decade using cytoreductive surgery (CRS) plus HIPEC for selected patients with colorectal PC who are amenable to complete macroscopic resection. This is the first trial to evaluate the specific role of HIPEC, after CRS, for the treatment of PC of colorectal origin. Methods: Prodige 7 is a randomized phase III, multicenter trial. Patients with histologically proven and isolated PC, peritoneal cancer index (PCI) ≤25 were eligi...
Published on Jan 18, 2018in The New England Journal of Medicine70.67
Willemien J. van Driel8
Estimated H-index: 8
(NKI-AVL: Netherlands Cancer Institute),
Simone N. Koole1
Estimated H-index: 1
(NKI-AVL: Netherlands Cancer Institute)
+ 14 AuthorsHenriette J.G. Arts18
Estimated H-index: 18
Abstract Background Treatment of newly diagnosed advanced-stage ovarian cancer typically involves cytoreductive surgery and systemic chemotherapy. We conducted a trial to investigate whether the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery would improve outcomes among patients who were receiving neoadjuvant chemotherapy for stage III epithelial ovarian cancer. Methods In a multicenter, open-label, phase 3 trial, we randomly assigned 245 patients...
Published on Oct 1, 2017in Diseases of The Colon & Rectum4.09
Jon D. Vogel22
Estimated H-index: 22
(Case Western Reserve University),
Cagla Eskicioglu2
Estimated H-index: 2
(Case Western Reserve University)
+ 2 AuthorsScott R. Steele30
Estimated H-index: 30
The American Society of Colon and Rectal Surgeons is dedicated to ensuring high-quality patient care by advancing the science, prevention, and management of disorders and diseases of the colon, rectum, and anus. The Clinical Practice Guidelines Committee is composed of society members who are chosen
Published on Mar 1, 2017in Colorectal Disease3.00
Charlotte E. L. Klaver4
Estimated H-index: 4
(UvA: University of Amsterdam),
H. Groenen1
Estimated H-index: 1
(UvA: University of Amsterdam)
+ 3 AuthorsP. J. Tanis22
Estimated H-index: 22
(UvA: University of Amsterdam)
Published on Nov 1, 2016in Anz Journal of Surgery1.60
Nayef A. Alzahrani9
Estimated H-index: 9
(UNSW: University of New South Wales),
Jorgen S. Ferguson1
Estimated H-index: 1
(UNSW: University of New South Wales)
+ 3 AuthorsDavid L. Morris64
Estimated H-index: 64
(UNSW: University of New South Wales)
Background Peritoneal carcinomatosis (PC) results from the secondary spread of many intraabdominal tumour types, such as colorectal malignancy (colorectal cancer, CRC), disseminated peritoneal adenomucinosis (DPAM), appendiceal cancer, ovarian carcinoma, sarcoma or from the occurrence of primary peritoneal disease such as peritoneal mesothelioma. The combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has seen improvements in survival in selected case...
Published on Aug 1, 2016in Annals of Oncology14.20
Eric Van Cutsem119
Estimated H-index: 119
(Katholieke Universiteit Leuven),
Andrés Cervantes55
Estimated H-index: 55
(University of Valencia)
+ 44 AuthorsG. Bodoky12
Estimated H-index: 12
The clinical outcome for patients with metastatic CRC (mCRC) has improved greatly over the last 20 years. These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particula...
Cited By0
Newest